238 related articles for article (PubMed ID: 21289075)
1. Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6.
Sridar C; Snider NT; Hollenberg PF
Drug Metab Dispos; 2011 May; 39(5):782-8. PubMed ID: 21289075
[TBL] [Abstract][Full Text] [Related]
2. The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6.
Snider NT; Sikora MJ; Sridar C; Feuerstein TJ; Rae JM; Hollenberg PF
J Pharmacol Exp Ther; 2008 Nov; 327(2):538-45. PubMed ID: 18698000
[TBL] [Abstract][Full Text] [Related]
3. Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.
Snider NT; Walker VJ; Hollenberg PF
Pharmacol Rev; 2010 Mar; 62(1):136-54. PubMed ID: 20133390
[TBL] [Abstract][Full Text] [Related]
4. A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist.
Snider NT; Nast JA; Tesmer LA; Hollenberg PF
Mol Pharmacol; 2009 Apr; 75(4):965-72. PubMed ID: 19171674
[TBL] [Abstract][Full Text] [Related]
5. Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides.
Snider NT; Kornilov AM; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2007 May; 321(2):590-7. PubMed ID: 17272674
[TBL] [Abstract][Full Text] [Related]
6. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system.
Cravatt BF; Lichtman AH
Curr Opin Chem Biol; 2003 Aug; 7(4):469-75. PubMed ID: 12941421
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.
Dickason-Chesterfield AK; Kidd SR; Moore SA; Schaus JM; Liu B; Nomikos GG; Felder CC
Cell Mol Neurobiol; 2006; 26(4-6):407-23. PubMed ID: 16736384
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin.
Holt S; Paylor B; Boldrup L; Alajakku K; Vandevoorde S; Sundström A; Cocco MT; Onnis V; Fowler CJ
Eur J Pharmacol; 2007 Jun; 565(1-3):26-36. PubMed ID: 17397826
[TBL] [Abstract][Full Text] [Related]
9. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.
Moreira FA; Kaiser N; Monory K; Lutz B
Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes.
Walker VJ; Griffin AP; Hammar DK; Hollenberg PF
J Pharmacol Exp Ther; 2016 Jun; 357(3):537-44. PubMed ID: 27000802
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.
Castelli MP; Paola Piras A; D'Agostino A; Pibiri F; Perra S; Gessa GL; Maccarrone M; Pistis M
Eur J Pharmacol; 2007 Nov; 573(1-3):11-9. PubMed ID: 17644084
[TBL] [Abstract][Full Text] [Related]
12. Endocannabinoids in the intact retina: 3 H-anandamide uptake, fatty acid amide hydrolase immunoreactivity and hydrolysis of anandamide.
Glaser ST; Deutsch DG; Studholme KM; Zimov S; Yazulla S
Vis Neurosci; 2005; 22(6):693-705. PubMed ID: 16469181
[TBL] [Abstract][Full Text] [Related]
13. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.
Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Dec; 600(1-3):50-8. PubMed ID: 18762181
[TBL] [Abstract][Full Text] [Related]
14. Temporal and spatial distribution of the cannabinoid receptors (CB1, CB2) and fatty acid amide hydroxylase in the rat ovary.
Bagavandoss P; Grimshaw S
Anat Rec (Hoboken); 2010 Aug; 293(8):1425-32. PubMed ID: 20665820
[TBL] [Abstract][Full Text] [Related]
15. FAAH and anandamide: is 2-AG really the odd one out?
Di Marzo V; Maccarrone M
Trends Pharmacol Sci; 2008 May; 29(5):229-33. PubMed ID: 18394720
[TBL] [Abstract][Full Text] [Related]
16. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption.
Rossi F; Siniscalco D; Luongo L; De Petrocellis L; Bellini G; Petrosino S; Torella M; Santoro C; Nobili B; Perrotta S; Di Marzo V; Maione S
Bone; 2009 Mar; 44(3):476-84. PubMed ID: 19059369
[TBL] [Abstract][Full Text] [Related]
17. Normal aging in rats and pathological aging in human Alzheimer's disease decrease FAAH activity: modulation by cannabinoid agonists.
Pascual AC; Martín-Moreno AM; Giusto NM; de Ceballos ML; Pasquaré SJ
Exp Gerontol; 2014 Dec; 60():92-9. PubMed ID: 25456842
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of fatty acid amide hydrolase unmasks CB1 receptor and TRPV1 channel-mediated modulation of glutamatergic synaptic transmission in midbrain periaqueductal grey.
Kawahara H; Drew GM; Christie MJ; Vaughan CW
Br J Pharmacol; 2011 Jul; 163(6):1214-22. PubMed ID: 21175570
[TBL] [Abstract][Full Text] [Related]
19. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition.
Scherma M; Medalie J; Fratta W; Vadivel SK; Makriyannis A; Piomelli D; Mikics E; Haller J; Yasar S; Tanda G; Goldberg SR
Neuropharmacology; 2008 Jan; 54(1):129-40. PubMed ID: 17904589
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase.
Pacher P; Bátkai S; Osei-Hyiaman D; Offertáler L; Liu J; Harvey-White J; Brassai A; Járai Z; Cravatt BF; Kunos G
Am J Physiol Heart Circ Physiol; 2005 Aug; 289(2):H533-41. PubMed ID: 15821037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
